Quintiles Recieves Phase II/III Clinical Research Industry Accolade
News May 22, 2013
Quintiles is the industry leader that best differentiates itself on service quality in Phase II/III clinical research, according to 157 pharmaceutical and biotechnology professionals who responded to Industry Standard Research’s (ISR) 2013 CRO Quality Benchmarking Report – Phase II/III. Respondents also rated Quintiles as the leader among large CROs for customer loyalty, defined by overall satisfaction, willingness to recommend and likelihood to use Quintiles again.
“We are deeply committed to helping our customers increase their probability of success at every stage of the product lifecycle,” said Paula Brown Stafford, President, Clinical Development at Quintiles. “We are delighted to see that our leadership and commitment to both quality and customer satisfaction are recognized by the industry.”
According to the report:
• Quintiles is the best Phase II/III clinical research service provider at differentiation based on service quality;
• Quintiles leads large CROs in customer loyalty and is the most cited industry leader;
• Quintiles most consistently meets customer expectations, and is the leader among large CROs in exceeding expectations for global reach, breadth of services, local regulatory knowledge, commercial market knowledge and the ability to consistently meet “First Patient In” timelines.
Survey respondents also recognized Quintiles as a leader among large CROs for meeting customer expectations for real-time access to data. Quintiles is committed to transforming drug development through its data and proprietary knowledge engine, Quintiles Infosario®, an innovative solution that seamlessly integrates data, Quintiles’ systems, processes and therapeutic expertise to help customers make faster, more informed decisions.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018